Review of Intravenous and Subcutaneous Electronic Glucose Management Systems for Inpatient Glycemic Control

Curr Diab Rep. 2020 Nov 9;20(12):68. doi: 10.1007/s11892-020-01364-2.


Purpose of review: The goal of this review is to summarize current literature on electronic glucose management systems (eGMS) and discuss their benefits and disadvantages in the inpatient setting.

Recent findings: We review different versions of commercially available eGMS: Glucommander™ (Glytec, Greenville, SC), EndoToolR (MD Scientific LLC, Charlotte, NC), GlucoStabilizer™ (Medical Decision Network, Charlottesville, VA), GlucoCare™ (Pronia Medical Systems, KY), and discuss advantages such as reducing rates of hypoglycemia, hyperglycemia, and glycemic variability. In addition, eCGMs offer a uniform standard of care and may improve workflows across institutions as well reduce barriers. Despite ample literature on intravenous (IV) versions of eGMS, there is little published research on subcutaneous (SQ) insulin guidance. Although use of eGMS requires extensive training and institution-wide adoption, time spent on diabetes management is better facilitated by their use.

Keywords: Electronic glucose management system; EndoToolR; GlucoCare™; GlucoStabilizer™; Glucommander™; Inpatient diabetes management.

Publication types

  • Review

MeSH terms

  • Blood Glucose
  • Electronics
  • Glucose*
  • Glycemic Control
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Inpatients*
  • Insulin


  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Glucose